Maurizio Serati1, Umberto Leone Roberti Maggiore2,3, Paola Sorice1, Simona Cantaluppi1, Enrico Finazzi Agrò4, Fabio Ghezzi1. 1. Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy. 2. Academic Unit of Obstetrics and Gynaecology, IRCCS AOU San Martino-IST, Largo R. Benzi 10, 16132, Genoa, Italy. ulrm@me.com. 3. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy. ulrm@me.com. 4. Department of Experimental Medicine and Surgery, University Tor Vergata, Rome, Italy.
Abstract
INTRODUCTION AND HYPOTHESIS: No previous studies have investigated the efficacy of mirabegron 50 mg as the first-line therapy in OAB patients. Hence, the primary objective of this study was to evaluate the efficacy of mirabegron in treatment-naive patients in comparison with those who had discontinued antimuscarinic therapy because of insufficient efficacy. METHODS: All consecutive women who had pure OAB symptoms (including urgency with or without urgency incontinence and frequency) for at least 3 months were considered for this study. Women were divided into two groups: women without any previous pharmacological treatment for OAB (group 1) and women with a previous history of failed antimuscarinics therapy (group 2). RESULTS: At 3-month follow-up, the objective results on the basis of the frequency-volume chart showed a significant improvement in both groups. Furthermore, a significant reduction in the Overactive Bladder Questionnaire Short Form (OABq-SF) score and in the Indevus Urgency Severity Scale (IUSS) questionnaire were reported in both groups. However, the improvement in objective and subjective outcomes was superior in group 1 to that in group 2. CONCLUSIONS: Mirabegron is efficacious in improving OAB symptoms in both naïve patients and those who discontinued primary antimuscarinic therapy; however, its efficacy is superior when prescribed as first-line therapy.
INTRODUCTION AND HYPOTHESIS: No previous studies have investigated the efficacy of mirabegron 50 mg as the first-line therapy in OABpatients. Hence, the primary objective of this study was to evaluate the efficacy of mirabegron in treatment-naive patients in comparison with those who had discontinued antimuscarinic therapy because of insufficient efficacy. METHODS: All consecutive women who had pure OAB symptoms (including urgency with or without urgency incontinence and frequency) for at least 3 months were considered for this study. Women were divided into two groups: women without any previous pharmacological treatment for OAB (group 1) and women with a previous history of failed antimuscarinics therapy (group 2). RESULTS: At 3-month follow-up, the objective results on the basis of the frequency-volume chart showed a significant improvement in both groups. Furthermore, a significant reduction in the Overactive Bladder Questionnaire Short Form (OABq-SF) score and in the Indevus Urgency Severity Scale (IUSS) questionnaire were reported in both groups. However, the improvement in objective and subjective outcomes was superior in group 1 to that in group 2. CONCLUSIONS: Mirabegron is efficacious in improving OAB symptoms in both naïve patients and those who discontinued primary antimuscarinic therapy; however, its efficacy is superior when prescribed as first-line therapy.
Entities:
Keywords:
Antimuscarinic; Female; Medical treatment; Mirabegron; Overactive bladder
Authors: Evann E Hilt; Kathleen McKinley; Meghan M Pearce; Amy B Rosenfeld; Michael J Zilliox; Elizabeth R Mueller; Linda Brubaker; Xiaowu Gai; Alan J Wolfe; Paul C Schreckenberger Journal: J Clin Microbiol Date: 2013-12-26 Impact factor: 5.948
Authors: Joachim W Thüroff; Paul Abrams; Karl-Erik Andersson; Walter Artibani; Christopher R Chapple; Marcus J Drake; Christian Hampel; Andreas Neisius; Annette Schröder; Andrea Tubaro Journal: Eur Urol Date: 2010-11-24 Impact factor: 20.096
Authors: F Bunn; M Kirby; E Pinkney; L Cardozo; C Chapple; K Chester; F Cruz; F Haab; C Kelleher; I Milsom; K D Sievart; A Tubaro; A Wagg Journal: Int J Clin Pract Date: 2014-12-11 Impact factor: 2.503
Authors: Bernard T Haylen; Dirk de Ridder; Robert M Freeman; Steven E Swift; Bary Berghmans; Joseph Lee; Ash Monga; Eckhard Petri; Diaa E Rizk; Peter K Sand; Gabriel N Schaer Journal: Int Urogynecol J Date: 2009-11-25 Impact factor: 2.894
Authors: P Abrams; C Kelleher; D Staskin; R Kay; A Martan; I Mincik; D Newgreen; A Ridder; A Paireddy; R van Maanen Journal: World J Urol Date: 2016-08-11 Impact factor: 4.226
Authors: Christopher R Chapple; Steven A Kaplan; David Mitcheson; Jiri Klecka; Jana Cummings; Ted Drogendijk; Caroline Dorrepaal; Nancy Martin Journal: Eur Urol Date: 2012-11-06 Impact factor: 20.096
Authors: Jan Krhut; Alois Martan; Roman Zachoval; Tomas Hanus; Lukas Horcicka; Kamil Svabík; Peter Zvara Journal: Int Urol Nephrol Date: 2018-01-10 Impact factor: 2.370